Form 4: EcoR1 Capital Increases Stake in Zymeworks Inc. with Recent Stock Purchases

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through multiple stock purchases in early April 2025.

Summary

• EcoR1 Capital, LLC, along with Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P., have reported changes in their beneficial ownership of Zymeworks Inc. common stock.
• On April 3, 2025, Qualified Fund purchased 120,770 shares at a weighted average price of $11.8421, with prices ranging from $11.8101 to $11.9123.
• On April 4, 2025, Qualified Fund purchased 196,438 shares at a weighted average price of $11.1679, with prices ranging from $10.9804 to $11.2921.
• Following these transactions, Qualified Fund holds 16,591,501 shares of Zymeworks Inc. common stock.
• EcoR1 Capital, as the investment advisor to the Funds, may be deemed to indirectly beneficially own these shares, and Mr. Nodelman may be deemed to indirectly beneficially own them as the control person of EcoR1.
• The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A major shareholder increasing their stake suggests confidence, but it's a routine filing and doesn't provide deep insight into the company's performance.

Positives

• Increased investment by a major shareholder, EcoR1 Capital, could signal confidence in Zymeworks' future prospects.

Industry Context

This activity reflects investment decisions within the biotechnology sector, where firms like Zymeworks are subject to ongoing scrutiny regarding their financial health and clinical trial progress. Institutional investors' actions, such as EcoR1's increased stake, are closely watched as indicators of confidence in a company's prospects.

Comparison to Industry Standards

• Comparing EcoR1's investment to similar moves by other biotech-focused funds could provide context.
• For example, Baker Bros. Advisors and OrbiMed Advisors are known for significant investments in biotech companies.
• Analyzing the timing and size of their investments relative to company milestones (e.g., clinical trial results, regulatory approvals) can offer insights.
• Comparing Zymeworks' valuation metrics (e.g., market cap, price-to-sales ratio) to peers like Seagen or BioNTech can also be informative.

Stakeholder Impact

• Increased investment could positively influence shareholder confidence.
• The transactions do not appear to have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Zymeworks, EcoR1 Capital, Stock Purchase, Beneficial Ownership, Oleg Nodelman, Qualified Fund, ZYME